Jim Pearce

Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.

Analyst Articles

As we noted in last week’s alert, Ekso Bionics (EKSO) announced last Tuesday that it would raise additional capital by issuing 3.75 million new shares of common stock at a price of $4.00 per share. On Friday, the company confirmed that it had successfully closed that offering, generating… Read More

This morning Ekso Bionics Holdings (EKSO) announced it will raise $15 million via a secondary offering of 3,750,000 million shares of common stock at a price of $4.00 per share. This announcement was accompanied by confirmation that the company’s stock has been approved for listing on the Nasdaq Capital… Read More

It was just five weeks ago that the two stocks highlighted in my June 17th article, “Top Tech Takeover Targets”, Applied Optoelectronics (AAOI) and Synaptics (SYNA), popped in value thanks to unexpected good news. In the case of Applied Optoelectronics, that news was in the form of an endorsement… Read More

Although it was only two months ago that I identified Synpatics (SYNA) as one of my two “Top Tech Takeover Targets”, recently released insider trading activity by the company’s officers suggest they don’t have much confidence in the company’s future. Over the past six months, every one of the… Read More

What Is Trump’s Deal?

We have to be careful when drawing conclusions about a president’s affect on stock market and the economy. For example, traditionally the pro-business Republican Party is regarded as good for the stock market, while the more regulatory-minded Democratic Party is viewed as an impediment to economic growth. However, no evidence supports those… Read More

As we reported in our Alert last week, shares of Argos Therapeutics took a hit after the company announced terms of an upcoming secondary stock offering that took the market by surprise. The company is raising another $50 million with this offering, in addition to the $60 raised from… Read More

Balm for Gilead

Shares of Personal Finance Growth Portfolio holding Gilead Sciences (GILD) dropped nearly 9% in early trading on Tuesday after the company released its third quarter earnings report that fell short of last year’s results. Quarterly revenue of $7.8 billion this year was less than last year’s sales of $8.2 billion,… Read More